Ownership and insider activity for Co-Diagnostics, Inc. (CODX): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting.
Price
| Price | $0.94 |
| Market Cap | $1M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-02 | Bohrer Daniel | |||
| 2026-05-23 | Egan Dwight H | A-Award | 4,584 | |
| 2026-05-23 | Egan Dwight H | D-Return | 1,633 | $8K |
| 2026-05-23 | Egan Dwight H | M-Exempt | 4,584 | |
| 2026-05-23 | Brown Brian Lee | A-Award | 3,750 | |
| 2026-05-23 | Brown Brian Lee | D-Return | 1,350 | $7K |
| 2026-05-23 | Brown Brian Lee | M-Exempt | 3,750 | |
| 2026-05-23 | Abbott Richard David | M-Exempt | 1,890 | |
| 2026-05-23 | Abbott Richard David | A-Award | 1,890 | |
| 2026-05-23 | Abbott Richard David | D-Return | 680 | $3K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $998737 | $3.5M | $950237 | $893138 | $43.0M | $88.6M | $23.0M | $14.9M | $2.9M | $11.9M |
| Short-term Investments | 0 | 0 | 0 | 0 | $4.3M | $1.3M | $58.3M | $43.6M | $26.8M | 0 |
| Receivables | $3183 | 0 | $13420 | $131382 | $12.1M | $20.9M | $5.4M | $330881 | $132570 | $190375 |
| Inventory | 0 | $9068 | $18153 | $197168 | $8.0M | $2.0M | $5.3M | $1.7M | $1.1M | $992397 |
| Total Current Assets | $1.2M | $4.5M | $1.1M | $1.6M | $68.4M | $115.1M | $92.7M | $62.1M | $32.3M | $13.7M |
| Property, Plant & Equipment | $87429 | $165567 | $156138 | $196832 | $949639 | $1.9M | $2.9M | $6.0M | $4.9M | $3.5M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | $14.7M | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | $27.2M | $26.8M | $26.4M | $26.1M | $7.2M |
| Total Assets | $1.3M | $4.7M | $1.6M | $2.2M | $71.2M | $160.0M | $123.1M | $95.3M | $64.0M | $24.7M |
| Accounts Payable | $104934 | $40819 | $148967 | $5959 | $598318 | $607506 | $952296 | $1.5M | $3.3M | $1.9M |
| Short-term Debt | $2.9M | 0 | $1.9M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $3.8M | $628256 | $2.4M | $328070 | $4.1M | $12.6M | $3.9M | $5.7M | $7.3M | $3.5M |
| Long-term Debt | $445000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $574301 |
| Total Liabilities | $4.3M | $811802 | $2.6M | $478070 | $4.5M | $25.6M | $8.6M | $9.3M | $9.7M | $4.1M |
| Retained Earnings | -$5.5M | -$12.4M | -$18.7M | -$25.0M | $17.5M | $54.2M | $39.9M | $4.6M | -$33.0M | -$80.4M |
| Total Equity | -$3.0M | $3.9M | -$1.1M | $1.7M | $66.7M | $134.5M | $114.5M | $86.0M | $54.3M | $20.6M |
| Total Debt | $3.4M | 0 | $1.9M | 0 | 0 | 0 | $347917 | $3.0M | $2.2M | $1.2M |
| Net Debt | $2.4M | -$3.5M | $958335 | -$893138 | -$47.3M | -$89.9M | -$80.9M | -$55.6M | -$27.6M | -$10.6M |
| Working Capital | -$2.6M | $3.8M | -$1.3M | $1.3M | $64.3M | $102.5M | $88.9M | $56.4M | $25.0M | $10.2M |
Financial Health
| Debt / Equity | 0.14 |
| Current Ratio | 1.81 |
| Piotroski F-Score | 1 |
| Altman Z-Score | -7.22 |
Profitability
| Return on Equity | -210.99% |
| Return on Invested Capital | -200.40% |
| Return on Assets | -283.63% |
| Gross Margin | 8.07% |
| Operating Margin | -4170.14% |
| Net Margin | -6523.04% |
Related companies: ADGM · AEMD · ALUR · DWTX · NVNO · PRPH · SINT
Explore sector: Healthcare · Biotechnology
More sections of CODX: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks